By IDSE News Staff
The FDA approved tafenoquine (Krintafel, GlaxoSmithKline [GSK] and Medicines for Malaria Venture), a single-dose medication for the radical cure of Plasmodium vivax malaria in patients 16 years of age and older who are receiving appropriate antimalarial therapy for acute P. vivax infection.
The approval was based on safety and efficacy data from a comprehensive global clinical development P. vivax radical cure program. The primary evidence for the clinical efficacy and safety